Watch RAPP. Know when insiders buy.
One email the day a filing lands. Free.
Work order
39
FLAG · insiders 25, shorts 53
Insiders, 90 days
−$3.5M
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.2BP/E —DIV YIELD —FCF YIELD -4.42%REV TTM —NET INCOME −$137.2MNET CASH —52W 22.40 – 52.50SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$60.8M | −$56.6M | — | -1.19 | −$41.5M | $78K | −$41.5M | Aug 5 |
| Q1 2026 · Mar 31 | $20M | — | — | −$24.2M | −$19.9M | — | -0.42 | −$13.1M | $86K | −$13.1M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$38.5M | −$33.8M | — | -0.71 | −$24.7M | $169K | −$24.9M | Mar 10 |
| Q3 2025 · Sep 30 | — | — | — | −$30M | −$26.9M | — | -0.71 | −$17.5M | $134K | −$17.6M | Nov 6 |
| Q2 2025 · Jun 30 | $0 | — | — | −$29.5M | −$26.7M | — | -0.75 | −$25.1M | $22K | −$25.1M | Aug 5 |
| Q1 2025 · Mar 31 | $0 | — | — | −$27.1M | −$24.1M | — | -0.68 | −$20.2M | $291K | −$20.5M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$23.5M | −$20M | — | -0.12 | −$14.4M | $226K | −$14.7M | Mar 10 |
| Q3 2024 · Sep 30 | — | — | — | −$21.6M | −$17.5M | — | -0.50 | −$16.4M | $140K | −$16.6M | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$20.8M | −$18.1M | — | -1.70 | −$16.4M | $967K | −$17.3M | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$17.1M | −$22.7M | — | -11.07 | −$17.6M | $1.1M | −$18.7M | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$14.8M | −$13.5M | — | -8.38 | −$10.4M | $1.4M | −$11.8M | Mar 11 |
| Q3 2023 · Sep 30 | — | — | — | −$9.6M | −$8.7M | — | -5.70 | −$5.4M | $52K | −$5.5M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$125.1M | −$111.5M | — | -2.86 | −$87.5M | $616K | −$88.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$83.1M | −$78.3M | — | -3.78 | −$64.8M | $2.4M | −$67.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$36.2M | −$34.8M | — | -23.10 | −$27.2M | $1.6M | −$28.8M | — | — |
Every number comes from Rapport Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.